{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:53:18Z","timestamp":1793148798484,"version":"4.5.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2016,10,1]]},"DOI":"10.1001\/jamaoncol.2016.1279","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T16:04:24Z","timestamp":1471449864000},"page":"1310","source":"Crossref","is-referenced-by-count":477,"title":["Prevalence of\n                    <i>ESR1<\/i>\n                    Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer"],"prefix":"10.1001","volume":"2","author":[{"given":"Sarat","family":"Chandarlapaty","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sung","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaksandra","family":"Samoila","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoqi","family":"You","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trusha","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Patel","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Voi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[{"name":"Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Moynahan","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9472","key":"coi160027r1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"coi160027r2","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi160027r3","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"coi160027r4","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer.","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"coi160027r5","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer.","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi160027r6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"coi160027r7","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"coi160027r8","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"313","key":"coi160027r9","doi-asserted-by":"publisher","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci Transl Med"},{"issue":"33","key":"coi160027r10","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi160027r11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer.","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"coi160027r12","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/1078-0432.CCR-15-1534","article-title":"Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients.","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"coi160027r13","doi-asserted-by":"publisher","first-page":"e0136407","DOI":"10.1371\/journal.pone.0136407","article-title":"Exome Sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease.","volume":"10","author":"Butler","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"coi160027r14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1373\/clinchem.2015.238717","article-title":"Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.","volume":"61","author":"Guttery","year":"2015","journal-title":"Clin Chem"},{"issue":"5","key":"coi160027r15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2.","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2542919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T11:01:09Z","timestamp":1540897269000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2016.1279"}},"subtitle":["A Secondary Analysis of the BOLERO-2 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2016.1279","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}